Skip to main content
VECTUS BIOSYSTEMS LIMITED logo

VECTUS BIOSYSTEMS LIMITED — Investor Relations & Filings

Ticker · VBS ISIN · AU000000VBS9 ASX Professional, scientific and technical activities
Open in API
Filings indexed 314 across all filing types
Latest filing 2023-04-26 Interim / Quarterly Rep…
Country AU Australia
Listing ASX VBS

About VECTUS BIOSYSTEMS LIMITED

https://vectusbiosystems.com.au/

Vectus Biosystems Limited is a drug discovery and development company focused on creating therapeutic candidates for the treatment of fibrosis and hypertension. The company utilizes a proprietary library of mimetic compounds to address tissue scarring and organ damage in the heart, kidneys, and liver. Its lead drug candidate, VB0004, is designed to treat high blood pressure and reverse established fibrosis. Complementing its pharmaceutical research, the company developed the Accugen platform, which provides a system for the precise quantification of DNA and RNA through quantitative polymerase chain reaction (qPCR) technology. By focusing on the reversal of fibrotic damage rather than symptom management, the company seeks to address significant unmet needs in chronic disease management and regenerative medicine.

Recent filings

Filing Released Lang Actions
Quarterly Activities/Appendix 4C Cash Flow Report 7 pages 338.8KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Quarterly Activities Report and Appendix 4C' and references compliance with ASX Listing Rule 4.7B, which mandates quarterly reporting. It includes detailed financial data such as consolidated statements of cash flows for the quarter ended 31 March 2023, commentary on company activities during the quarter, patent updates, and cash flow analysis. The document is approximately 15,000 characters long, indicating it is a full report rather than a brief announcement. The presence of substantive financial data and analysis for a period shorter than a full fiscal year confirms it is an Interim / Quarterly Report. Therefore, the appropriate classification is 'IR' (Interim / Quarterly Report).
2023-04-26 English
Notification regarding unquoted securities - VBS 7 pages 30.6KB
Share Issue/Capital Change Classification · 100% confidence The document is a notification regarding the issue of unquoted equity securities, specifically unquoted options issued under an employee incentive scheme. It details the number of securities issued, their terms, issue date, and compliance with ASX listing rules. The content focuses on the issuance of new securities rather than financial results, management changes, or other report types. This fits the definition of a Share Issue/Capital Change announcement, which covers new share issues or capital changes. The document length is over 7,000 characters and contains detailed issuance information, not just a brief announcement or link to a report, so it is not a Report Publication Announcement or Regulatory Filing. Therefore, the appropriate classification is SHA (Share Issue/Capital Change).
2023-04-25 English
Vectus to present at NWR Virtual Healthcare Conference 1
Investor Presentation Classification · 85% confidence The document is an announcement dated 16 March 2023 from Vectus Biosystems Limited about an upcoming presentation at the NWR Virtual Healthcare Conference. It provides details about the presentation date, time, and how to register or access the recording. The content focuses on informing shareholders, investors, and interested parties about the event and does not contain any financial data, regulatory filings, or detailed report content. The document length is 3470 characters, which is relatively short and consistent with an announcement rather than a full report or transcript. There is no indication that this is a transcript of the presentation or a detailed investor presentation document. Therefore, the document best fits the category of an Investor Presentation announcement or notice about an upcoming presentation event. However, since it is primarily an announcement about the presentation rather than the presentation material itself, the closest fitting category is Investor Presentation (IP), as it relates to a presentation for investors focusing on company information and strategy.
2023-03-15 English
Half Yearly Report & Appendix 4D 20 pages 2.1MB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Half Year Report' and references the six months ended 31 December 2022, indicating it is a financial report for a half-year period. It includes detailed financial data such as revenues, net loss, net tangible assets, and dividends. It also contains a Directors' Report, condensed consolidated financial statements, notes to the financial statements, and an Independent Auditor's Review Report. The document discusses operational activities, clinical trial progress, intellectual property, and financing activities including share placements and convertible note conversions. The length of the document (15,000 characters) and the presence of substantive financial data and analysis confirm it is a comprehensive interim financial report rather than a brief announcement or certification. Therefore, the document fits the definition of an Interim / Quarterly Report (IR).
2023-02-23 English
Quarterly Activities/Appendix 4C Cash Flow Report 7 pages 408.8KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Quarterly Activities Report and Appendix 4C' and references compliance with ASX Listing Rule 4.7B, which mandates quarterly reporting. It includes detailed financial data such as cash flow statements, financing activities, and operational commentary for the quarter ended 31 December 2022. The content includes actual financial figures, cash flow analysis, and operational updates for the quarter, which aligns with the characteristics of an Interim / Quarterly Report. It is not merely an announcement or a brief summary but a comprehensive quarterly report with substantive financial data and analysis. Therefore, the document fits the definition of an Interim / Quarterly Report (IR).
2023-01-30 English
Response to ASX Appendix 3Y Query 4 pages 345.3KB
Regulatory Filings Classification · 95% confidence The document is a letter from ASX Listings Compliance to Vectus Biosystems Limited regarding a late lodgement of Appendix 3Y, which is a Change of Director's Interest Notice. The letter requests explanations and information about compliance with ASX Listing Rules 3.19A and 3.19B concerning director disclosures of interests and transactions in securities. The response letter from Vectus Biosystems confirms the late lodgement was due to an administrative oversight and describes the arrangements in place to ensure compliance. The document is primarily correspondence about regulatory compliance and disclosure of director share transactions, not the actual Appendix 3Y form or a financial report. It is a regulatory filing related to director dealings but does not itself report the transactions in the formal Appendix 3Y format. Therefore, the document fits best under Regulatory Filings (RNS) as it is a compliance and disclosure correspondence rather than a formal Director's Dealing report (DIRS) or other specific filing type.
2023-01-29 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.